Biogen buys rights to Alzheimer's treatments from Eisai


Biogen Idec (BIIB) has purchased the rights to two experimental treatments for Alzheimer's disease from Japan's Eisai.

Biogen will pay Eisai an unspecified amount upfront and milestones. If the drugs, called E2609 and BAN2401, are commercialized, the companies will share the profits.

Eisai (ESALF) will lead the development of the therapies and pursue regulatory authorization, although both companies will co-promote the drugs in the U.S., Europe and other markets.

"Eisai's candidates have demonstrated compelling early data and complement our Alzheimer's disease research while extending our pipeline in this critical area," says Biogen CEO George Scangos.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs